Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
- Details
- Category: GlaxoSmithKline
Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate.
Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
- Details
- Category: Sanofi
Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Sanofi will support manufacturing of Janssen's COVID-19 vaccine in order to address the COVID-19 pandemic and supply needs. Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization for its single-dose Janssen COVID-19 vaccine candidate and an application for conditional marketing authorisation to the European Medicines Agency.
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of investigational single-shot Janssen COVID-19 vaccine candidate
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial.
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
The expanded collaboration, which builds on the agreement signed in 2020 to research and develop therapies for coronaviruses,
Pfizer and BioNTech commence global clinical trial to evaluate COVID-19 vaccine in pregnant women
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in preventing COVID-19 in healthy pregnant women 18 years of age and older.
European Commission purchases additional 150 million doses of COVID-19 vaccine Moderna
- Details
- Category: Business
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an additional 150 million doses of the COVID-19 Vaccine Moderna, which are scheduled to be delivered in the third and fourth quarter of 2021.
AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
- Details
- Category: AstraZeneca
AstraZeneca's COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65.
More Pharma News ...
- U.S. government purchases additional 100 million doses of Moderna's COVID-19 vaccine
- CureVac initiates rolling submission with European Medicines Agency for COVID-19 vaccine candidate, CVnCoV
- Sinovac receives conditional marketing authorization in China for its COVID-19 vaccine
- Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
- AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
- Pfizer and BioNTech publish data from in vitro studies demonstrating COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with key mutations present in U.K. and South African variants
- Johnson & Johnson announces submission of application to the U.S. FDA for Emergency Use Authorization of its investigational single-shot Janssen COVID-19 vaccine candidate